This symposium took place on 14th September 2017 as a part of the 26th European Academy of Dermatology and Venereology (EADV) congress in Geneva, Switzerland
Chairperson: Bernd Bonnekoh1
Speakers: Jorge Juan Fernández García,2 Christian Surber,3 Anthony Bewley4
1. Clinic for Dermatology, Otto-von-Guericke University, Magdeburg, Germany
2. E-Health Innovation Department, Sant Joan de Déu Hospital; MOEBIO/d-HEALTH, Barcelona, Spain
3. Department of Dermatology, University Hospital of Basel, Basel; Department of Dermatology, University Hospital Zürich, Zürich, Switzerland
4. Barts Health NHS Trust; College of Medicine, Queen Mary University of London, London, UK
Disclosure: Prof Surber has acted as a consultant to Actelion Pharmaceuticals, Basilea Pharmaceutica, Bitsplitters, CureVac, Galderma, Janssen Research and Development, LEO Pharma, Regensdorf-Watt, Novartis Consumer Health, Novartis International, Ultrasun, and Spirig Pharma. Dr Bewley has acted as an ad hoc consultant to AbbVie, Almirall, Galderma, Janssen, LEO Pharma, Lilly, Novartis, Stiefel (GSK), and Thornton & Ross, and as a medical advisor to Changing Faces, the National Eczema Society, and the Psoriasis Association. Prof Bonnekoh has functioned as a consultant and/or referent and/or participant in clinical studies for AbbVie, Biogen, Dermapharm, Janssen, LEO Pharma, Eli Lilly and Company, Novartis, Pfizer, and Stiefel (GSK). Mr Fernández has declared no conflicts of interest.
Acknowledgements: Writing assistance was provided by Sarah von Riedemann, SCRIPT, Toronto, Canada.
Support: The publication of this article was funded by LEO Pharma. LEO Pharma was able to review the content of the manuscript for medical/scientific accuracy but otherwise had no role in content development of the publication. The views and opinions expressed are those of the authors and not necessarily of LEO Pharma or the EADV.
Citation: EMJ Dermatol. 2017;5:36-43.
The main objectives of this symposium were to review the importance of topical therapies in the treatment of psoriasis and the unmet clinical and patient quality of life (QoL) needs that still exist, to discuss the innovation seen with reformulations of existing active pharmaceutical ingredients (API), and to align changes in future dermatology practice with these topical treatment innovations. Mr Fernández introduced the topic of ‘looking to the future’, with a wide-ranging, big-picture view of the changing face of medical practice and the increasing role of technology, including specific examples of how these trends will affect dermatology practice. Prof Surber built on the theme of innovation to discuss how novel products and approaches can be pursued in dermatology, particularly in the area of topical psoriasis treatments. Prof Surber’s presentation and the subsequent talk by Dr Bewley described how innovations can translate into improved patient outcomes in key areas, including psoriasis control, itching, sleep, and overall health-related QoL. Prof Bonnekoh tied the various threads of the symposium together by showing how the new technological and pharmacological options could help clinicians evolve their overall approach to long-term topical management of psoriasis, moving from a more reactive mindset to safe and effective proactive control. Finally, the audience was given the opportunity to ask questions in a brief panel discussion.
This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.